Art's Way Announces Fiscal 2024 Results, Led By Strong Year From Modular Building Segment And Improved Liquidity Despite Difficult AG Conditions

Stock Information for XTL Biopharmaceuticals Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XTL Biopharmaceuticals Ltd.

Art's Way Reports Improved Results With Modular Buildings Growth Offsetting Ag Market Challenges
Art's Way Improves Profitability Despite Ongoing AG Market Headwinds
Art's Way Manufacturing Improves Results Despite Ag Market Turmoil; Modular Building Segment Continues to Thrive
Art's Way Manufacturing Reports Progress Despite Difficult Market Conditions in Third Quarter of Fiscal 2024; CEO Transition
Art's Way Scientific's Fiscal 2024 Performance Continues to Build Off 2023; Art's Way Ag Continues to Fight the Headwinds of the North American Farm Sector
Art's Way Scientific's Growth Surges Forward for Fiscal 2024; Art's Way AG Utilizes Momentum for Difficult AG Market Ahead
Art's Way Announces 18% Revenue Increase, 104% Increase in Income From Continuing Operations
Art's Way Announces Revenue Growth for Q3 and First Nine Months of Fiscal 2023, Earnings Growth for the Nine Months Ended August 31, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.